Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact
Loading...
Official URL
Full text at PDC
Publication date
2017
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
American Society for Microbiology
Citations
Exportar
Citation
Galar A, Valerio M, Muñoz P, Alcalá L, García-González X, Burillo A, Sanjurjo M, Grau S, Bouza E. Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00687-17. doi: 10.1128/AAC.00687-17. PMID: 28739788; PMCID: PMC5610525.
Abstract
Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.